Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...
Fisher’s 13F portfolio value decreased from ~$165B to ~$141B in Q2 2022. Johnson & Johnson and Capital One Financial were increased while reducing Eli Lilly and Novo Nordisk this quarter. The top three positions are Apple, Microsoft, and Amazon. They add up to ~15% of t...
Reproxalap seems poised for FDA approval for dry eye disease. Therapy has clear practical advantages over Restasis and Xiidra. Monetization event seems likely. Insider buying resumes. In June 2021, I authored the article, Aldeyra Therapeutics : A New Approach To Ocul...
Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety. The restructuring of the company offers a...
Novartis AG (NVS) Q2 2022 Results Conference Call July 19, 2022 08:00 AM ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Matthew Weston - Credit Suisse Tim Anderson - Wolfe ...
Novartis today reported results for HY 2022. Sales in the Innovative Medicines segment continue to grow strongly, and Novartis has several promising blockbuster drugs for a broad range of indications. Share buybacks, enabled through the sale of Novartis' stake in Roche, will likely re...
Q2 performance is in line with analyst estimates. The company delivered a good set of numbers. Sandoz's strategic review is ongoing and the generic division is also delivering better results. Novartis reaffirms 2022 guidance, and we confirm our buy rating. When we init...
The following slide deck was published by Novartis AG in conjunction with their 2022 Q2 earnings call. For further details see: Novartis AG 2022 Q2 - Results - Earnings Call Presentation
The street consensus anticipates 10.10% net profit and 6.77% free cash flow CAGR for Roche over the next 5 years. Ocrevus holds 20% of the global multiple sclerosis market share. An advantageous risk-reward profile is limiting the downside, while my valuation model values the Roch...
AlphaFold is a leading open-source AI program that aids researchers in visualizing protein structures. Applications are diverse and reduce research time across the healthcare industry and academia. The program certainly is a gift to our future health, but the open source nature an...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...